Impact of aminoglycoside cycling in six tertiary intensive care units: Prospective longitudinal interventional study

Croatian Medical Journal

Volumn 49, Issue 2, 2008, Pages 207-214

  Francetić, Igor ^a   Kalenić, Smilja ^a   Huić, Mirjana ^a   Merčep, Iveta ^a   Makar Aušperger, Ksenija ^a   Likić, Robert ^a   Erdeljić, Viktorija ^a   Tripković, Vesna ^a   Šimić, Petra ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; GENTAMICIN; NETILMICIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY;

AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; CROATIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENTAMICINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LONGITUDINAL STUDIES; NETILMICIN; PROSPECTIVE STUDIES; SEPSIS;

EID: 43449136787     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2008.2.207     Document Type: Article

References (30)

1. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999;74:519-28.
2. Flournoy DJ, Reinert RL, Bell-Dixon C, Gentry CA. Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. Am J Infect Control. 2000;28:244-50.
3. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211-5.
4. Bryan LE. General mechanisms of resistance to antibiotics. J Antimicrob Chemother. 1988;22 Suppl A:1-15.
5. Wright GD. Mechanisms of resistance to antibiotics. Curr Opin Chem Biol. 2003;7:563-9.
6. Larson TA, Garrett CR, Gerding DN. Frequency of aminoglycoside 6′-N-acetyltransferase among Serratia species during increased use of amikacin in the hospital. Antimicrob Agents Chemother. 1986;30:176-8.
7. Betts RF, Valenti WM, Chapman SW, Chonmaitree T, Mowrer G, Pincus P, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med. 1984;100:219-22.
8. Lee JT Jr. Three-year experience with amikacin sulfate as an exclusive surgical aminoglycoside in a large acute-care hospital. Am J Med. 1985;79:37-42.
9. Peetermans WE, Bobbaers HJ. Amikacin as first-choice aminoglycoside in a medical intensive care unit: a one-year bacteriological surveillance study. J Chemother. 1996;8:17-24.
10. Friedland IR, Funk E, Khoosal M, Klugman KP. Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother. 1992;36:1596-600.
11. Gerding DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol. 2000;21(1 Suppl):S12-7.
12. Brown EM, Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother. 2005;55:6-9.
13. Bennett KM, Scarborough JE, Sharpe M, Dodds-Ashley E, Kaye KS, Hayward TZ III, et al. Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J Trauma. 2007;63:307-11.
14. Berk SL, Alvarez S, Ortega G, Verghese A, Holtsclaw-Berk SA. Clinical and microbiologic consequences of amikacin use during a 42-month period. Arch Intern Med. 1986;146:538-41.
15. Dubberke ER, Fraser VJ. Cycling and other strategies to slow and reverse antibiotic resistance. Infect Med. 2004;21:544-56.
16. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: National Committee for Clinical Laboratory Standards. Vol 10. 2nd ed. Villanova (PA): NCCLS publication 1990. M7-A2.
17. Collaborating WHO. Centre for Drug Statistics Methodology. ATC Index with DDDs. Oslo: WHO; 2003.
18. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003; 16:430-50.
19. Guven GS, Uzun O. Principles of good use of antibiotics in hospitals. J Hosp Infect. 2003;53:91-6.
20. Merz LR, Warren DK, Kollef MH, Fridkin SK, Fraser VJ. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections. Chest. 2006;130:1672-8.
21. Martinez JA, Nicolas JM, Marco F, Horcajada JP, Garcia-Segarra G, Trilla A, et al. Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med. 2006;34:329-36.
22. Sommers BD. Economics of antibiotic administration. Crit Care Nurs Clin North Am. 2003;15:89-96.
23. Tambic Andrasevic A, Tambic T, Kalenic S, Jankovic V; Working Group of the Croatian Committee for Antibiotic Resistance Surveillance. Surveillance for antimicrobial resistance in Croatia. Emerg Infect Dis. 2002;8:14-8.
24. Barsic B, Tambic A, Santini M, Klinar I, Kutlesa M, Krajinovic V. Antibiotic resistance among nosocomial isolates in a Croatian intensive care unit - results of a twelve-year focal surveillance of nosocomial infections. J Chemother. 2004;16:273-81.
25. Warren DK, Hill HA, Merz LR, Kollef MH, Hayden MK, Fraser VJ, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med. 2004;32:2450-6.
26. van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, et al. Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med. 2005;171:480-7.
27. Kalenic S, Francetic I, Polak J, Zele-Starcevic L, Bencic Z. Impact of ampicillin and cefuroxime on bacterial colonization and infection in patients on a neonatal intensive care unit. J Hosp Infect. 1993;23:35-41.
28. Kalenic S, Sekulic A, Francetic I, Scap M, Justinic Z. Empirical therapy of sepsis based on local resistance at neurosurgical intensive care unit. Neurol Croat. 1993;42:47-56.
29. Pirson M, Dramaix M, Struelens M, Riley TV, Leclercq P. Costs associated with hospital-acquired bacteraemia in a Belgian hospital. J Hosp Infect. 2005;59:33-40.
30. Inan D, Saba R, Gunseren F, Ongut G, Turhan O, Yalcin AN, et al. Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC Infect Dis. 2005;5:5.